Pathway enrichment analysis based on these DMG identified differentially methylated pathways where significant differences were observed by comparing anti-CCP3(−) Controls, At-Risk and Early RA participants for each lineage with the most significant differences appearing in memory T cells and B cells (FDR < 0.1, see Fig. 1d and Supplementary Table 1). The gene discussed is AGBL3; the disease is rheumatoid arthritis.